MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
A legfontosabb adatok
- Ki végzi
- Thomas Jefferson University
- Hol
- Philadelphia (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 6 fő vett részt
- Kezdés
- 2022. nov. 16.
- Befejezés
- 2025. okt. 24.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- MRI-guided Intensity-Modulated Radiation Therapy
- Antiandrogen Therapy
- PSMA PET Scan
- Computed Tomography
- Magnetic Resonance Imaging
- Bone Scan
- Biospecimen Collection
- Quality-of-Life Assessment
- A regiszteradat frissítve
- 2026. március 3.
- Miért állt le
- Loss of required MRI resources needed to conduct protocol-specified procedures
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Age: above 18 years
- Participants must be histologically proven, adenocarcinoma prostate
- Localized to the prostate without positive pelvic lymph node involvement
- No distant metastatic disease assessed by pretreatment PSMA PET or bone scan and CT scan
- High risk prostate cancer as defined by National Comprehensive Cancer Network (NCCN): Gleason score of 8- 10, clinical stage T3a or higher, or prostate specific antigen (PSA) > 20 ng/mL
- Ability to receive long term hormone therapy
- Karnofsky performance score (KPS) > 70
- No prior history of therapeutic irradiation to pelvis
- Patient willing and reliable for follow-up and quality of life (QOL)
- English speaking/reading
Ki nem vehet részt
- Previous radiation therapy (RT) to prostate or prostatectomy
- A previous trans-urethral resection of the prostate (TURP)
- Severe urinary symptoms or with severe International Prostate Symptom Score (IPSS) score despite being on hormonal therapy for 6 months which in the opinion of the physician precludes RT
- Any contraindication to radiotherapy such as inflammatory bowel disease
- Life expectancy < 2 years
- Evidence of distant or pelvic metastasis at any time since presentation
- Patients with known obstructive symptoms with stricture
Helyszínek itt: Egyesült Államok
- Sidney Kimmel Cancer Center at Thomas Jefferson UniversityPhiladelphia, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This phase II trial tests whether magnetic resonance imaging (MRI)-guided hypofractionated radiation therapy works to reduce treatment time and side effects in patients with high risk prostate cancer. MRI-guided hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time directly to diseased tissue, reducing damage to healthy tissue. Using MRI-guided radiation therapy on areas of the prostate and pelvic lymph nodes may shorten overall treatment time compared to the longer standard of care therapy and may reduce the number and/or duration of side effects.
A vizsgálat csoportja
- Treatment (MRI-guided IMRT, ADT)A vizsgált kezelés
Patients undergo MRI-guided IMRT on study and receive SOC ADT throughout the trial. Patients may also undergo PSMA PET, CT, MRI, and bone scans at screening and undergo collection of blood samples throughout the trial.
Kezelés: MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, Biospecimen Collection és Quality-of-Life Assessment
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase 2 Study of Extreme Hypofractionation Including Pelvic Nodes for High Risk Prostate Cancer Using MgRT (MRI Guided Radiation Therapy)
- A regiszteradat frissítve
- 2026. március 3.